H.C. Wainwright Maintains Their Buy Rating on Autolus Therapeutics Plc (AUTL)


H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Autolus Therapeutics Plc (AUTL) today and set a price target of $45. The company’s shares opened today at $31.01.

Chattopadhyay commented:

“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.46, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.0% and a 48.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Autolus Therapeutics Plc with a $45 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $53.24 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 59.89K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts